IDEAYA to Present IDE892 Phase 1 Data at London R&D Day
Image
SOUTH SAN FRANCISCO – November 04, 2026 -- IDEAYA Biosciences (NASDAQ: IDYA) will hold an Investor R&D Day in London on Nov. 16, 2026, at 5:00 PM GMT, presenting Phase 1 dose-escalation data for its PRMT5 inhibitor IDE892 and outlining targeted 2027 clinical milestones.
The oncology company will also appear at two sell-side conferences in London that week. CEO Yujiro S. Hata will join a fireside chat at the UBS Global Biopharma Conference on Nov. 16 at 10:40 AM GMT, hosted by Michael Yee. On Nov. 17 at 1:00 PM GMT, Hata, R&D President Michael White and CFO Joshua Bleharski will appear at the Jefferies Global Healthcare Conference, hosted by analyst Maury Raycroft.